Rex Clements

Rex is a recognised, well-rounded leader, with a proven track record in the pharmaceutical industry. He brings more than 20 years of rich experience, gained across multiple assignments in the sector.

He has a dual MBA in Strategy and General Management from the Wharton School of the University of Pennsylvania, USA, and a Bachelor of Science in Chemical Engineering from the University of Stellenbosch, South Africa. In the early stages of his career, Rex worked in consultancy, spending six years as an Associate in McKinsey & Company in Chicago, USA.

Since 2010, Rex has worked at Sandoz, a Novartis division and global leader in generic pharmaceuticals and biosimilars, where he held a range of roles, including Head of Global Franchises, Business Unit Head of Anti-Infectives & API, Cluster Head for Northern Europe & General Manager Nordics, General Manager United Kingdom & Ireland, and Head of Strategy for Technical Operations.

In his two most recent roles as Head of Global Franchises and Business Unit Head of Anti-Infectives & API between 2015 and 2019, Rex served a member of the Sandoz Executive Committee.

Rex joined Centrient Pharmaceuticals in March 2020 and, alongside his role as Chief Executive Officer, is a member of the Centrient Management Board of Directors.